Obesity Featured Articles

  1. Are Your Trial Payments Creating Hidden Compliance Risks? 7/13/2026

    Clear separation of reimbursements, stipends, and site payments helps reduce compliance risk, improve transparency, and support ethical compensation.

  2. What Happens When Trial Services Don't Talk To Each Other? 7/13/2026

    Fragmented trial services slow progress. A unified approach to logistics, payments, and data streamlines operations and supports patient-centric trials.

  3. Before You Invest: A Clinical Trial Payment Technology Checklist 7/13/2026

    Outdated payment workflows create delays, financial blind spots, and administrative strain in clinical trials. Evaluating integrated, real-time solutions helps reduce burden, improve visibility, and support more efficient, scalable trial execution.

  4. Best-In-Class Solutions Accelerate Development Of GLP-1 Therapeutics 7/13/2026

    As metabolic trials expand, success hinges on mitigating participant fatigue, offering culturally tailored dietary support, and designing inclusive protocols to retain a truly diverse cohort.

  5. Do You Know Today, What Your Trial Will Spend Tomorrow? 7/13/2026

    Fragmented data and outdated forecasting can derail trial budgets. Real-time financial and operational insights improve accuracy and spending control.

  6. The Clinical Trial Inefficiencies Hiding in Plain Sight 7/13/2026

    Clinical trials are often slowed by disconnected systems. Centralizing payments, logistics, and data helps streamline operations and retain patients.

  7. It's A Mad Men World For IRB Review Of Clinical Trial Advertisements 7/13/2026

    Modern digital tools and AI have transformed clinical trial recruitment, outpacing decades-old regulations. Discover how to apply core ethical principles to protect participant privacy and equity.

  8. Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development 7/13/2026

    UCB’s Senior Development Strategy Lead Pediatrics Martine Dehlinger-Kremer, Ph.D., discusses updates to the new EU Pharma legislation and how they impact pediatric drug development, including earlier pediatric investigational plans .

  9. Why Life Science Tech Pilots Fail After The Demo — And How To Avoid It 7/13/2026

    A working demo might look promising, but it doesn't tell you whether the tech can be shipped, integrated, validated, and accepted by regulator. Tech consultant Lukasz Lazewski explains how to look past the allure and evaluate its true functionality.

  10. Interpreting Early Inflammation Signals: What Early Human Data Tells Us 7/10/2026

    Early inflammatory signals can mislead without context. Benchmarked human challenge models reveal true biological activity, guiding decisions on mechanism, dosing, and clinical development.